QUIXIN
LOE ApproachingNDAOPHTHALMICSOLUTION/DROPSPriority Review
Approved
Aug 2000
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUIXIN is an ophthalmic solution approved in 2000 for eye infections and inflammatory conditions. As a small-molecule fluoroquinolone antibiotic delivered via topical drops, it works by inhibiting bacterial DNA gyrase. The product is currently approaching loss of exclusivity.
LOE Approaching
With moderate competitive pressure (30) and approaching LOE, QUIXIN teams are transitioning from growth management to lifecycle extension and generic defense strategies, likely with reduced headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
QUIXIN roles are concentrated in Asia-Pacific markets (Japan, Singapore, Thailand), reflecting Santen's geographic footprint and manufacturing centers. Career opportunities are focused on market defense, regulatory compliance, and sales in mature markets rather than growth innovation.
[Singapore] Global Safety Vigilance Risk Management Lead[Japan] Manager
Worked on QUIXIN at Santen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.